Thyrocare Reports Strong Q2FY27 Results – Revenue Up 25.1%, PAT before Exceptional Items Up 25.7%

·       The most exciting part of this year’s journey is specialty. We took the Thyrocare playbook of scale, reach and affordability into specialty diagnostics, starting with allergy and genomics, and the business is now live and gaining steady traction. We call this journey - From Routine to Remarkable - The next frontier of Diagnostics.

·       Thyrocare launches Pregnancy Test Kit, a rapid home-testing solution that delivers results in just five minutes and backed by a confirmatory lab test. We have onboarded actress Yami Gautam as our brand ambassador to strengthen awareness and consumer outreach for this product. We have launched this with the help of our API Holdings group company Ascent and are already present in more than 10,000 chemists.     

·     Consolidated revenue registered a 25.1% year-on-year growth, driven primarily by a 26.7% increase in the Pathology segment.

·     In the Pathology business, franchise revenue grew by 26.9% year-on-year, while partnership revenue recorded 27.9% year-on-year growth.

·     Thyrocare, India’s largest diagnostic test volume processor, processed 61.6 million tests in Q2FY27, marking a strong 27.4% year-on-year growth and reinforcing its volume leadership position in the industry.

·     Consolidated EBITDA grew by 24.9% year-on-year to Rs 89.3 Cr, and Profit After Tax (PAT) before exceptional items grew by 25.7% year-on-year to Rs 60.2 Cr

·     The exceptional item represents a one-time, non-cash impairment charge of Rs 45 Cr relating to NHL in consolidated books, recognised in connection with the definitive term sheet for the sale of the NHL business. This charge does not impact the Company’s operational performance.

·     Sustained Six Sigma quality standards, reducing complaints per million tests to 2.90 (down 24% YoY) with ATAT at 3.49 hours.

Thyrocare Reports Strong Q2FY27 Results – Revenue Up 25.1%, PAT before Exceptional Items Up 25.7%

The Company delivered a robust performance in Q2FY27, with consolidated revenue of ₹270.8 crore, up 25.1% year-on-year, led by continued momentum in the Pathology segment, which grew 26.7% YoY. EBITDA rose 24.9% YoY to ₹89.3 crore. PAT before exceptional items surged 25.7% YoY to ₹60.2 crore, underscoring the Company’s focus on profitable growth.

Exceptional items comprise a one-time, non-cash impairment charge of ₹45 crore relating to NHL, recognised in the consolidated financial statements in connection with the definitive term sheet for the proposed sale of the NHL business. This charge has no impact on the Company’s operational performance. Thyrocare has issued a postal ballot seeking shareholders’ approval for the proposed divestment of its Nuclear Imaging business, enabling the Company to sharpen its focus and allocate capital towards its Pathology business, which offers a stronger growth trajectory, higher margins and better return on capital employed (ROCE).

Thyrocare, India’s largest diagnostic test volume processor, further strengthened its leadership position during the quarter, processing 61.6 million tests, up 27.4% year-on-year. The Pathology business maintained strong traction, with franchise revenue up 26.9% and partnership revenue up 27.9% year-on-year.

Thyrocare’s commitment to quality continued to deliver Six Sigma-level performance, with complaints reduced to 2.9 per million (down 24% YoY) and an average turnaround time (ATAT) of 3.49 hours from sample receipt.

Thyrocare continued its expansion into specialty diagnostics, marking the next phase of its growth journey. Having commenced with allergy and genomics, the Company is progressively expanding its specialty test portfolio, with a focus on building clinical trust through scientific rigour, uncompromising quality and industry-leading turnaround times.

Thyrocare also launched its Pregnancy Test Kit, a rapid home-testing solution that delivers results in just five minutes and is the first kit in India backed by a confirmatory lab test. The Company has onboarded actress Yami Gautam as brand ambassador to strengthen awareness and consumer outreach for this product. We have launched this with the help of our API Holdings group company Ascent and are already present in more than 10,000 chemists.

Senior management remarks:

“Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India. I am particularly excited about our foray into Point of Care devices with a unique proposition and soon hope to be present in all major chemist outlets.”

– Rahul Guha, MD & CEO, Thyrocare Technologies Ltd

Consolidated Financial Performance for Q2FY27

About Thyrocare

Thyrocare Technologies Limited (NSE: THYROCARE, BSE: 539871) is India’s first fully automated diagnostic laboratory chain, with a strong pan-India presence. Thyrocare focuses on providing quality and affordable diagnostic services to patients, healthtech and wellness providers, insurance companies, pharmaceutical companies, franchisees, laboratories, hospitals and the government. Many leading healthcare product and services brands all over India use the comprehensive test profile menu offered by Thyrocare.

Thyrocare has an extensive network of laboratories across India, with 12,911 active franchisees during the quarter. In Q2FY27, it processed 61.6 million diagnostic